^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | cofetuzumab pelidotin (ABBV-647) (Microtubule inhibitor, PTK7-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
655O - Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)
Published date:
10/16/2023
Excerpt:
Cofe-P was well-tolerated with encouraging antitumor activity observed in rNSCLC and 30% ORR in the subpopulation with NSQ EGFR WT NSCLC and PTK7 ≥90%/≥2+.
Trial ID:
